Earlier Diagnosis and Better Treatment Mission Related to the Cohort Programme

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorLuxembourg Institute of Health

About this trial

The Luxembourg Parkinson's Study is an ongoing longitudinal nationwide monocentric observational study. It collects extensive clinical, molecular, genetic, and digital device-based longitudinal data, as well as foreseen post-mortem diagnostic validation (Hipp et al., 2018). The cohort consists of more than 1,600 participants from Luxembourg and the Greater Region, comprising patients with typical PD or atypical parkinsonism - irrespective of disease stage, age, cognitive status, comorbidities, or linguistic background - followed-up annually and age- and sex-matched healthy control subjects followed-up every 4 years. To provide a large, longitudinally followed, and deeply phenotyped set of patients and controls for clinical and fundamental research on PD, the investigators have implemented an open-source digital platform that has been partly harmonized with other international PD cohort studies. This effort is flanked by comprehensive biosampling efforts assuring high quality and sustained availability of body liquids and tissue biopsies (including blood, urine, stool, saliva, hair, skin biopsy and cerebrospinal fluid). All data and samples are stored, curated, and integrated into state-of-the-art data and biobank facilities.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Subjects with neurodegenerative disease or having Parkinson's disease (typical PD or atypical parkinsonism)

Subjects of all genders with a full capacity of consent

Subjects with a limited consent capacity if the legal guardian/authorised representative is in agreement

Subjects of at least 18 years of age at the time of inclusion

Disqualifiers

Refusal to sign the informed consent

Limited capacity of consent on the part of the donor, if there is no legally determined guardian/authorised representative, or the latter is not present or does not agree with the inclusion

Active cancer

Pregnant women

Trial population

Subjects with a neurodegenerative disease or having degenerative parkinsonism (typical PD or atypical parkinsonism) and gender- and age-matched healthy controls.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Observational study with sample and data collection

    Other intervention

    Observational study with sample and data collection

Treatment groups

1,800 Participants
are divided into 2 treatment groups
Group A: PD patients1 intervention
Group B: Healthy controls1 intervention

Trial outcomes

Primary outcomes

1

1. Establish an open collection of a large set of diverse longitudinal bio-samples and data for research in 800 PD patients and 800 controls

1.1. Samples will be aliquoted and stored according to the highest standards at the IBBL for future research.

Time frame
through study completion, an average of 8 years
2

2. Stratification of parkinsonism into subtypes and definition of individual progression trajectories of PD.

2.1. Identify PD patients' subgroups with a similar pattern of disease progression. datasets.

Time frame
through study completion, an average of 8 years
3

Determine Parkinson's disease biomarker signatures

3.1. Identify new and early diagnostic biomarkers

Time frame
through study completion, an average of 8 years
4

Develop a mechanistic understanding of the disease

4.1. Understand the mechanisms of PD pathogenesis.

Time frame
through study completion, an average of 8 years

Secondary outcomes

1

Inform future studies testing new therapies for Parkinson's disease

1.1. Enable future studies, such as clinical trials, by sharing the findings of mechanisms of PD pathogenesis and identifying new therapeutic targets.

Time frame
through study completion, an average of 8 years
2

Harmonization of data with international Parkinson's disease cohort studies

2.1. Data collected in this study will be harmonized with the international PD research community through an open-source digital platform.

Time frame
through study completion, an average of 8 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Luxembourg Institute of Health

Lead sponsor

University of Luxembourg

Collaborator

Laboratoire National de Santé (LNS)

Collaborator

Centre Hospitalier du Luxembourg

Collaborator